Good David M, Thongboonkerd Visith, Novak Jan, Bascands Jean-Loup, Schanstra Joost P, Coon Joshua J, Dominiczak Anna, Mischak Harald
Department of Chemistry, University of Wisconsin-- Madison, Madison, Wisconsin 53706, USA.
J Proteome Res. 2007 Dec;6(12):4549-55. doi: 10.1021/pr070529w. Epub 2007 Oct 31.
Sparked by the article from Lescuyer and colleagues in a recent issue, we aim here to further encourage interest in and discussion of clinically relevant biomarker research. We express our view on proteomics for biomarker discovery by addressing multiple relevant issues, including the inherent differences between biological fluids (and how these differences affect current analytical approaches) and experimental design to maximize the efficiency of moving from the bench to the bedside. Herein, we also include suggestions for definition of the term "biomarker", based on the use of a set of universal characterization/validation requirements, and illustrate several recent examples of successful transitions of benchtop proteomic studies work to clinical practice.
受Lescuyer及其同事近期发表文章的启发,我们旨在进一步激发对临床相关生物标志物研究的兴趣并促进相关讨论。我们通过探讨多个相关问题来表达我们对用于生物标志物发现的蛋白质组学的看法,这些问题包括生物体液之间的固有差异(以及这些差异如何影响当前的分析方法)和实验设计,以最大限度地提高从实验室到临床应用的效率。在此,我们还基于一套通用的表征/验证要求,对“生物标志物”一词的定义提出了建议,并举例说明了近期一些将实验室蛋白质组学研究成功转化为临床实践的案例。